Neurodegeneration biomarkers investigated in AD include brain atrophy measured by MRI [3], decreased regional glucose metabolism assessed using fluorodeoxyglucose (FDG) PET [4], and increases in CSF proteins that may reflect damage, for example, Tau and neurofilament light (Nfl) [5,6]. The gene discussed is MAPT; the disease is Alzheimer disease.